60384-30-7

Usage

Uses

Used in Pharmaceutical Industry:
3α,7β-Diacetoxy-5β-cholan-24-oic acid methyl ester is used as a reactant for the preparation of bile acids and their metabolites. It plays a crucial role in the synthesis of novel bile acid-based therapeutic agents, which have potential applications in the treatment of various liver diseases, cholesterol-related disorders, and other health conditions.
Used in Chemical Research:
3α,7β-Diacetoxy-5β-cholan-24-oic acid methyl ester serves as an important intermediate in the development of new chemical entities and the study of bile acid chemistry. It can be used to explore the structure-activity relationships of bile acids and their derivatives, leading to the discovery of new compounds with improved pharmacological properties and therapeutic potential.
Used in Drug Development:
3α,7β-Diacetoxy-5β-cholan-24-oic acid methyl ester is utilized in the design and development of innovative drug candidates targeting various diseases and conditions. Its unique structural features allow for the creation of new molecules with enhanced efficacy, selectivity, and safety profiles, making it a valuable asset in the field of drug discovery and development.

Upstream product

• 10538-55-3 3α,7β-dihydroxy-5β-cholan-24-oic acid methyl ester 
• 108-24-7 acetic anhydride 
• 128-13-2 ursodeoxycholic acid 
• 75-36-5 acetyl chloride 

Downstream Products

• 75672-24-1 methyl ursodeoxycholate 7-acetate 

Relevant academic research and scientific papers

Preparation method of 3beta-ursodesoxycholic acid

The invention discloses a synthesis method of 3beta-ursodesoxycholic acid. The method comprises following steps: ursodesoxycholic acid is taken as a raw material and subjected to esterification, 3-position and 7-position hydroxyl groups, selective removal of a 3-position protecting group, oxidization of the 3-position hydroxyl group, reduction into 3beta hydroxyl group and hydrolysis of 7-positionand 24-position hydroxyl groups, and 3beta-ursodesoxycholic acid is obtained. The synthesis method is novel, lower in cost, high in yield, simple and convenient to operate and environmentally friendly, and conditions are mild.

Novel liver-specific nitric oxide (NO) releasing drugs with bile acid as both NO carrier and targeting ligand

Novel liver-specific nitric oxide (NO) releasing drugs with bile acid as both the NO carrier and targeting ligand were designed and synthesized by direct nitration of the hydroxyl group in bile acids or the 3-O-hydroxyl alkyl derivatives, with the intact 24-COOH being preserved for hepatocyte specific recognition. Preliminary biological evaluation revealed that oral administrated targeted conjugates could protect mice against acute liver damage induced by acetaminophen or carbon tetrachloride. The nitrate level in the liver significantly increased after oral administration of 1e while nitrate level in the blood did not significantly change. Co-administration of ursodeoxycholic acid (UDCA) significantly antagonized the increase of nitrate in the liver resulted by administration of 1e.